IDEX CORP /DE/ (IEX) Form 8-K — Oct 28, 2026
IDEX Corporation reported record third quarter 2026 results, with net sales of $951.7 million up 8% on both a reported and organic basis and orders of $991.2 million up 13%. Reported diluted EPS was $1.95 and record adjusted diluted EPS was $2.33, both up 15% year-over-year, with adjusted EBITDA of $264.8 million and a 27.8% margin. The Health & Science Technologies segment led with 14% sales growth, driven by AI-related demand for data center power and semiconductor markets. The company raised full-year 2026 guidance, now expecting organic sales growth of 6.5% to 6.8% and adjusted diluted EPS of $8.91 to $8.96, up from prior guidance of $8.70 to $8.85.
Key figures
- Eps
- 1.95
- Revenue
- 951.7
- Guidance
- Full year organic sales +6.5% to 6.8% (up from 5% to 6%); full year adjusted diluted EPS of $8.91 to $8.96, up ~12% YoY at midpoint (up from $8.70 to $8.85)
- Net Income
- 144.1
- Revenue Yoy
- 8% reported and organic
- Cash Position
- 602.1
- Shares Outstanding
- 73.7 million basic weighted average
- Orders
- $991.2 million, +13% reported and organic
- Gross Margin
- 45.1%
- Free Cash Flow
- 214.3
- Adjusted EBITDA
- 264.8
- Capital Returned
- $129 million via dividends and buybacks
- Fmt Segment Sales
- 327.9
- Hst Segment Sales
- 433.5
- Fsdp Segment Sales
- 191.5
- Operating Cash Flow
- 239.5
- Adjusted Diluted EPS
- 2.33
- Adjusted EBITDAMargin
- 27.8%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.